These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28711496)

  • 21. Identification of novel serum biomarker for the detection of acute myeloid leukemia based on liquid chromatography-mass spectrometry.
    Wang D; Tan G; Wang H; Chen P; Hao J; Wang Y
    J Pharm Biomed Anal; 2019 Mar; 166():357-363. PubMed ID: 30690249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics.
    Uemura N; Nakanishi Y; Kato H; Saito S; Nagino M; Hirohashi S; Kondo T
    Int J Cancer; 2009 May; 124(9):2106-15. PubMed ID: 19142970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer stem cell marker ALDH1 expression is associated with lymph node metastasis and poor survival in esophageal squamous cell carcinoma: a study from high incidence area of northern China.
    Wang Y; Zhe H; Gao P; Zhang N; Li G; Qin J
    Dis Esophagus; 2012 Aug; 25(6):560-5. PubMed ID: 22098156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of highly sensitive biomarkers that can aid the early detection of pancreatic cancer using GC/MS/MS-based targeted metabolomics.
    Hirata Y; Kobayashi T; Nishiumi S; Yamanaka K; Nakagawa T; Fujigaki S; Iemoto T; Kobayashi M; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Yamada T; Honda K; Azuma T; Yoshida M
    Clin Chim Acta; 2017 May; 468():98-104. PubMed ID: 28215548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of receptor for advanced glycation end products (RAGE) is related to prognosis in patients with esophageal squamous cell carcinoma.
    Tateno T; Ueno S; Hiwatashi K; Matsumoto M; Okumura H; Setoyama T; Uchikado Y; Sakoda M; Kubo F; Ishigami S; Shinchi H; Natsugoe S
    Ann Surg Oncol; 2009 Feb; 16(2):440-6. PubMed ID: 19023628
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TGFBI Expression in Cancer Stromal Cells is Associated with Poor Prognosis and Hematogenous Recurrence in Esophageal Squamous Cell Carcinoma.
    Ozawa D; Yokobori T; Sohda M; Sakai M; Hara K; Honjo H; Kato H; Miyazaki T; Kuwano H
    Ann Surg Oncol; 2016 Jan; 23(1):282-9. PubMed ID: 25448803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of serum biomarkers of chemoradiosensitivity in esophageal cancer via the targeted metabolomics approach.
    Fujigaki S; Nishiumi S; Kobayashi T; Suzuki M; Iemoto T; Kojima T; Ito Y; Daiko H; Kato K; Shouji H; Honda K; Azuma T; Yoshida M
    Biomark Med; 2018 Aug; 12(8):827-840. PubMed ID: 30043633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum metabolic profiling study of lung cancer using ultra high performance liquid chromatography/quadrupole time-of-flight mass spectrometry.
    Li Y; Song X; Zhao X; Zou L; Xu G
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Sep; 966():147-53. PubMed ID: 24856296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytokeratin 15 is an Effective Indicator for Progression and Malignancy of Esophageal Squamous Cell Carcinomas.
    Shen YH; Xu CP; Shi ZM; Zhang YJ; Qiao YG; Zhao HP
    Asian Pac J Cancer Prev; 2016; 17(9):4217-4222. PubMed ID: 27797221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SLC39A6: a potential target for diagnosis and therapy of esophageal carcinoma.
    Cui XB; Shen YY; Jin TT; Li S; Li TT; Zhang SM; Peng H; Liu CX; Li SG; Yang L; Li N; Hu JM; Jiang JF; Li M; Liang WH; Li Y; Wei YT; Sun ZZ; Wu CY; Chen YZ; Li F
    J Transl Med; 2015 Oct; 13():321. PubMed ID: 26444413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear PROX1 is Associated with Hypoxia-Inducible Factor 1α Expression and Cancer Progression in Esophageal Squamous Cell Carcinoma.
    Yokobori T; Bao P; Fukuchi M; Altan B; Ozawa D; Rokudai S; Bai T; Kumakura Y; Honjo H; Hara K; Sakai M; Sohda M; Miyazaki T; Ide M; Nishiyama M; Oyama T; Kuwano H
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1566-73. PubMed ID: 26310281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A plasma metabonomic analysis on potential biomarker in pyrexia induced by three methods using ultra high performance liquid chromatography coupled with Fourier transform ion cyclotron resonance mass spectrometry.
    Liu T; Li S; Tian X; Li Z; Cui Y; Han F; Zhao Y; Yu Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1063():214-225. PubMed ID: 28886580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening and verifying endometrial carcinoma diagnostic biomarkers based on a urine metabolomic profiling study using UPLC-Q-TOF/MS.
    Shao X; Wang K; Liu X; Gu C; Zhang P; Xie J; Liu W; Sun L; Chen T; Li Y
    Clin Chim Acta; 2016 Dec; 463():200-206. PubMed ID: 27784637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolomic-based biomarker discovery for non-invasive lung cancer screening: A case study.
    O'Shea K; Cameron SJ; Lewis KE; Lu C; Mur LA
    Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2682-7. PubMed ID: 27423423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolomic serum profiling detects early-stage high-grade serous ovarian cancer in a mouse model.
    Jones CM; Monge ME; Kim J; Matzuk MM; Fernández FM
    J Proteome Res; 2015 Feb; 14(2):917-27. PubMed ID: 25567202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy.
    Okamoto K; Ninomiya I; Ohbatake Y; Hirose A; Tsukada T; Nakanuma S; Sakai S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Hidehiro T; Takamura H; Fushida S; Ohta T
    Oncol Rep; 2016 Dec; 36(6):3333-3342. PubMed ID: 27748881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and Validation of Potential Serum Biomarkers for Pediatric Patients with Congenital Heart Diseases by Metabolomics.
    Yu M; Sun S; Yu J; Du F; Zhang S; Yang W; Xiao J; Xie B
    J Proteome Res; 2018 Oct; 17(10):3517-3525. PubMed ID: 30207476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LC-MS-based serum metabolomic analysis reveals dysregulation of phosphatidylcholines in esophageal squamous cell carcinoma.
    Mir SA; Rajagopalan P; Jain AP; Khan AA; Datta KK; Mohan SV; Lateef SS; Sahasrabuddhe N; Somani BL; Keshava Prasad TS; Chatterjee A; Veerendra Kumar KV; VijayaKumar M; Kumar RV; Gundimeda S; Pandey A; Gowda H
    J Proteomics; 2015 Sep; 127(Pt A):96-102. PubMed ID: 25982385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The metabolomic detection of lung cancer biomarkers in sputum.
    Cameron SJ; Lewis KE; Beckmann M; Allison GG; Ghosal R; Lewis PD; Mur LA
    Lung Cancer; 2016 Apr; 94():88-95. PubMed ID: 26973212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma.
    Matsuda T; Takeuchi H; Matsuda S; Hiraiwa K; Miyasho T; Okamoto M; Kawasako K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S356-64. PubMed ID: 24566863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.